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How the discovery of neuronal stem cells have 
changed neuroscience and perspective for the therapy 
for central nervous system illnesses
Abstract 
Mostly-incurable central nervous system diseases and disorders, such as 
neurodegenerative diseases, stroke, brain and spinal cord injuries and psy-
chiatric illnesses, represent one of the most difficult health problems today, 
in terms of mortality, disability, productivity loss and health-care costs. 
After disappointing results regarding the translational value of neuroprotec-
tive molecules and protocols from preclinical research on animals to clinic, 
a new hope for the developing effective treatments for brain and spinal cord 
disorders came with the discovery of neuronal stem and progenitor cells, 
which have the potential to differentiate into a myriad of different glial and 
neuronal cell types. The basic biology behind the neuronal stem cells is be-
coming discovered, paving the way to possibilities for their manipulation 
and reprograming and for their clinical applications. Some of those protocols 
and clinical trials are described in this paper, with the emphasis on spinal 
cord injury treatments. 
CentrAl nervous system (Cns) diseAses 
And disorders – the sCAle of the problem
Central nervous system diseases and disorders, such as stroke, brain or spinal cord injuries and neurodegenerative diseases like Alzheim-
er’s or Parkinson’s disease, represent the major disease burden worldwide 
in terms of mortality, disability, productivity loss and health-care costs, 
with still deficient and delayed treatment rates (74, 88). In Europe, 
disorders of the brain contribute to 26.6% of the total burden, thus a 
greater proportion as compared to other regions of the world (87). It has 
been estimated that the susceptibility and morbidity to acute disorders 
such as stroke as well as chronic neurodegenerative diseases, will increase 
almost exponentially as the lifespan of individuals increases globally 
(43). For example, it is supposed that mortality due to stroke (now the 
second leading cause of death and the leading cause of long term dis-
ability worldwide, for which there is limited treatment beyond the pri-
mary insult) will double by 2020 worldwide, owing to an aging popula-
tion and an increasing incidence in developing countries (47).
The core issue regarding the inexistent or inadequate therapy for most 
of CNS illnesses is the fact that, in contrast to some other tissues like 
skin or bones, the CNS, thus brain and spinal cord, has very limited 
capacity for self-recovery and regeneration in adults. Because of this 
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most important scientific and therapeutic challenges. The 
basic biological problem common to the most of the CNS 
injuries and diseases is the dysfunction and/or death of 
neuronal cells which are postmitotic cells unable to di-
vide, and therefore incapable of replacing neighboring 
dead or injured cells. Moreover, those neurons that sur-
vive the injury but have their axons damaged, show only 
limited capacity to regrow their neuronal fibers and to 
re-establish functional connections within specific neu-
ronal networks (71, 78). 
In recent years, important advances have been made 
in our understanding of the molecular pathways that are 
implicated in the pathogenesis of CNS diseases and that 
lead to cell dysfunction and cell death in Parkinson’s and 
Huntington’s diseases (33, 65, 66) or stroke (57). Those 
studies have identified molecular targets for candidate 
interventions designed to slow or reverse neurodegenera-
tive course and have pointed the way to develop mecha-
nisms-based neuroprotective strategies. Unfortunately, 
despite the discovery and development of many pre-clin-
ically promising neuroprotective molecules and proce-
dures and a large number of clinical trials, currently there 
is not even one neuroprotective drug shown to be success-
ful in functional recovery of patients after stroke or spinal 
cord injury or able to stop the progressive neurodegenera-
tive scenario in neurodegenerative diseases (16, 21, 40, 
76). Why the neuroprotective strategies that work in 
animals have either failed or have shown only a minimal 
effect when translated to humans is the matter of great 
debate (16). Factors like the complexity of the molecular 
and cellular pathways involved and the difficulty to com-
prehend and manipulate them are probably the leading 
cause. In recent years, the strategies focusing on the en-
dogenous brain and spinal cord immune cells are inten-
sively studied for the treatment of the CNS diseases, since 
it became clear that the immune cells are very important 
players in the pathology of different brain and spinal cord 
pathologies (68).
However, even if the neuroprotective drugs would be 
available, they would solve the problem of the acute and 
progressive conditions when neurons are rapidly dying, 
but they would not be useful for the chronic states when 
damage repair rather that neuroprotection becomes a cru-
cial goal.
The improvements in neural stem cell biology in the 
last 25 years, which are considered as the most extraordi-
narily productive quarter century in developmental neu-
roscience (22), have opened up new strategies for the treat-
ment of the brain and spinal cord diseases.
disCovery of neurAl stem/
progenitor Cells
For a long time it has been accepted that the adult 
mammalian central nervous system completely lacks re-
generative capability and that this state is fixed and im-
mutable. This dogma was removed with the discovery of 
neuronal stem and progenitor cells as a lifelong source of 
glia and neurons, changing dramatically our way of 
thinking about the CNS structure, development and plas-
ticity, and giving new hope for the treatment of CNS 
diseases and disorders (22). Neuronal stem cells are self-
renewing, multipotent cells that repeatedly produce more 
restricted neuronal progenitors, that divide just few times 
to produce a small number of differentiated progeny, giv-
ing finally birth to myriad types of neurons and glia (22). 
The neuronal stem cells (NSCs) and their progenitors are 
commonly referred as neural precursor cells (7) or, in this 
review, as neural stem/progenitor cells (NSPCs). 
The discovery of NSPCs has introduced new basic 
biological concepts regarding how individual transcrip-
tion factors can direct and reprogram cell fate, control cell 
proliferation and differentiation and also how extracel-
lular molecular cues can guide the complex but precise 
processes of NSPCs migration during development. In 
the 1960s the first reports appeared, based on autoradi-
ography, showing the existence of dividing cells in certain 
zones of the brain: in subependymal zone, later named 
subventrical zone (SVZ; frontal horns of the lateral ven-
tricles in the forebrain) and in the antero-lateral subgran-
ular zone (SGZ) of the hippocampal dentate gyrus (1, 2, 
4, 73). Later, these results were confirmed using advanced 
immuno-histological techniques combined with confocal 
microscopy and stereological techniques (19). Interest-
ingly, adult neurogenesis in humans has been also dem-
onstrated in cancer patients who were given BrdU for 
diagnostic purposes (Eriksson et al., 1989) and recently 
in the post-mortem hippocampal tissue of individuals 
born during the Cold War (1955-1963), taking advantage 
of the elevated atmospheric 14C levels caused by above-
ground nuclear bomb testings (75). 
The discoveries of the heterogeneous progenitor cells, 
with large proliferative potential that were able to produce 
both neuronal and glial progeny and had capacity of self-
renewal, a cardinal property of stem cells (10, 15, 32, 82), 
led to the concept that the nervous system develops from 
multipotent neuronal stem cells. Interestingly, even 
though neurogenesis is observed in the SGZ throughout 
the life, playing an essential role in memory functions (9), 
in the SVZ neurogenesis does not actually take place. 
Instead, the SVZ precursor cells have to migrate, in an 
ordinate pattern formation called rostral migratory 
stream, to the olfactory bulb to become neurons (3). It is 
also interesting that NSCs in SVZ stop generating neu-
rons in humans at about 2 years of age (62) and that their 
number declines with normal aging, and is dramatically 
reduced in Alzheimer’s disease (AD) patients (27). How 
the progressive, temporal restriction of the stem potential, 
when early progenitors with wide multipotency are 
changing to late progenitors, is controlled is not yet clear. 
Multiple cues, such as cytokine cardiotropin, transcrip-
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tion factors and epigenomic changes such as DNA meth-
ylation and chromatin modifications have been proposed 
(22). 
In the 1990s new results demonstrated that stress lev-
els, alcohol or antidepressant drugs negatively affect pro-
liferation of progenitors in the SGZ (24, 25). Conversely, 
adult neurogenesis is substantially increased by motor 
activity like running (84), signals from an enriched envi-
ronment (31) or learning processes (18). Recent evidence 
show that endogenous NPCs might also have non-neuro-
genic homeostatic functions via the release of different 
types of neuroprotective molecules important to health 
and disease conditions (9).
Furthermore, new progress has been made in our un-
derstanding of the location and constituents of stem cell 
“niches”, where neuronal stem cells are born and main-
tained (22). A neuronal stem cell niche is defined as a 
limited and specialized anatomical region in which stem 
cells reside, and includes astrocytes, endothelial cells, mi-
croglia and blood vessels that integrate local and system-
ic factors to allow stem cell proliferation, survival and 
differentiation (7). As neuronal stem cell niches turn out 
to be more complex than other cell niches in our body, 
our understanding of the molecules and events that regu-
late them needs to be largely amended.
neuronAl stem Cell mAnipulAtion 
And reprogrAmming
Further progress in the field has come with the devel-
opment of the techniques to isolate, propagate, differenti-
ate, transplant and genetically modify CNS stem cells. 
Importantly, it has been shown that neural progenitor 
cells retain their neurogenic potential when transplanted 
in vitro and that their neuronal differentiation can be 
stimulated by certain molecules such as Fibroblast 
Growth Factor -2, retinoic acid or forskolin (54), indicat-
ing that extrinsic factors play a major role in stimulation 
of neurogenesis. Moreover, it has been shown that NSPCs 
isolated from SVZ and transplanted into ectopic regions 
of the adult brain, differentiate into glial cells (oligoden-
drocytes and astrocytes) (67), but that the NSPCs iso-
lated from the spinal cord, which is considered to be non-
neurogenic region, when grafted into SGZ of the dentate 
gyrus can differentiate into neurons, supporting the idea 
that external cues from the local microenvironment pro-
mote neuronal differentiation of NSPCs (69). 
It has been initially shown that somatic cells can be 
reprogrammed by transferring their nucleus into enucle-
ated unfertilized oocytes (85) or by in vitro fusion with 
embryonic stem cells (12, 80), indicating that embryonic 
stem cells contain factors that can recover totipotency or 
pluripotency of somatic cells. These discoveries were fol-
lowed by one of the most striking invention in the field 
of stem cell biology: the development of a protocol to al-
low molecular reprograming of somatic cells (mouse fi-
broblasts) into embryonic-like induced pluripotent stem 
cells (iPSCs), which have the capacity to differentiate in 
any type of cell (81). Somatic cells were reprogramed by 
retroviral introduction of four transcription factors: 
Oct3/4, Sox2, c-Myc, and Klf4. The obtained iPSCs ex-
hibited cell marker genes, morphology and growth prop-
erties of embryonic stem cells, and their subcutaneous 
transplantation into nude mice resulted in formation of 
teratoma tumors (81). The authors won in 2012 Nobel 
Prize in Physiology and Medicine for these discoveries, 
which had a dramatic impact on modern biology, as a 
proof of principle that essentially all cells in our body 
maintain intrinsic plasticity for differentiating into di-
verse types of cell. Since then, many types of human iP-
SCs have been produced, giving hope for the clinical 
translation of these technical improvements to treat neu-
rodegenerative diseases (83), spinal cord injury (36), au-
tism (6), epilepsy (55) or other diseases (72). Some of these 
clinical trials will be described and discussed below. Nev-
ertheless, before these trials actually become routine 
clinical procedure, further advances in basic understand-
ing of neural stem biology is needed. 
Developments in the iPSCs and human fetal and em-
bryonic stem cells (hEMCs) technology are used not only 
for therapeutic interventions of CNS illnesses, but also to 
study human development and to model early-onset neu-
rodegenerative and neurodevelopmental diseases (22). In 
fact, many of these disorders, such as Huntington’s dis-
ease, familial dysautonomia, Rett’s syndrome or schizo-
phrenia, turn out to be related to inadequate neuronal 
maturation, synaptic deficits and failed neuronal connec-
tivity, all of which can be mimicked by targeted genome 
modifications of the iPSCs or hEMCs, which are then 
transplanted into in vivo animal models (8, 11, 35, 45, 
58). These novel interdisciplinary methods, bringing to-
gether basic cell and molecular biologists with bioengi-
neers and clinicians, are gradually complementing tradi-
tional studies on postmortem brain tissues or rodent 
models (46). One example of studying human CNS de-
velopment using stem cells is the transplantation of hu-
man NSPCs into the rodent brain, where they produce 
physiologically functional GABAergic interneurons, 
mimicking the human neuronal development (52). In 
another study, it was possible to produce chimeric mice 
with murine gray matter and predominantly human 
white matter, after neonatal transplantation of human 
glial progenitors into the brain of the shiverer demyelin-
ated mouse (86). The implanted human glial progenitor 
cells have produced functional oligodendrocytes that 
spread through the murine nervous system, suggesting 
the possibility that the neonatal transplantation of human 
glial progenitor cells can effectively treat disorders of con-
genital and perinatal hypomyelination (86). Another im-
portant aim of these studies is to clarify if the pathology 
of neurodegenerative and neurodevelopmental diseases is 
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restricted to neuronal cells only, or it may be also depen-
dent on the dysfunction of other neighboring cells present 
in the neuronal stem cell niche (22). 
trAnsplAntAtions of nspCs As 
novel therApeutiC strAtegies for 
Cns illness
The discovery of the neuronal stem cells has led to 
rapid recognition of their therapeutic potential, which was 
tested already in numerous clinical trials. Most of them 
are controlled trials, based on the use of defined human 
NSPCs products and on procedures previously tested in 
appropriate animal models which have provided proof of 
concept and safety data. The results have in general shown 
that neuronal stem cells might supply trophic and im-
munomodulatory factors to the injured nervous tissue, 
and may, thus, enhance axonal growth and remyelination 
of spared axons, and contrast neuroinflammation (23), 
with the possibility of generation of new neurons and 
their functional integration into existing neuronal circuits 
(13). The common problems related to transplantation-
based strategies are the need for embryonal or fetal cells 
with related ethical concerns, the risk of immune rejec-
tion and the oncogenic potential of autologous pluripo-
tent stem cells. An intense debate on the challenges to 
successful translation of promising experimental preclin-
ical studies to clinically efficacious treatments for patients 
is in progress (34).
The initial neuronal stem cell transplantations have 
been conducted using human embryonal and fetal neu-
ronal stem cells. Encouraging preliminary results are 
coming for example from the Phase I clinical trial for 
demyelinating Pelizaeus-Merzbacher disease (PMD), 
started in 2010 at the University of California, San Fran-
cisco, in which banked human neural stem cells HuCNS-
SCs (StemCell Inc.) were transplanted into children (four 
males, between 6 months and five years of age, with ge-
netic confirmation of PMD). The 2-year follow up report 
indicates safety of the procedure and the preliminary re-
sults show a small, positive outcome with progressive my-
elination in all four patients (Stem Cell press release: 
http://investor.stemcellsinc.com/phoenix.zhtml?c= 
86230&p=irol-newsArticle&ID=1678880&highlight=). 
The HuCNS-SCs have been also used in phase I/II clini-
cal trial for the Dry Age-Related Macular Degeneration 
(the leading cause of blindness in elderly) and for spinal 
cord injury (SCI). In Italy a Phase I clinical trial, started 
in 2011, has shown safety of a transplantation of human 
neural stem cells into spinal cord of 18 Amyotrophic lat-
eral sclerosis (ALS) patients (age between 20 and 75 
years). In the USA the first FDA-approved stem cell Phase 
I safety trial for ALS, based on the transplantation of hu-
man spinal cord stem cells directly into the gray matter 
of the spinal cord of 18 patients, is in progress. In pre-
clinical animal work, these neural stem cells have been 
shown to make synaptic contacts with the host motor 
neurons and to express neurotrophic growth factors, 
which are thought to be neuroprotective (91, 92, 89). 
neurAl stem Cells for sCi 
therApy
In contrast to neurodegenerative diseases such as Par-
kinson’s disease, where a specific population of neurons 
degenerate, spinal cord injury, as well as stroke or trau-
matic brain injury, affects a heterogeneous population of 
cell types over large regions, so that cell therapies should 
replace multiple cell populations, with their integration 
into appropriate and functional neuronal circuits, and 
reconstruction of the disrupted vascular system (39).
Clinical studies in which SCI patients received differ-
ent types of stem cell have been recently described (38, 
42, 70), attracting much public attention. Unfortunately, 
there is no fully documented functional benefit for the 
majority of the SCI patients recruited in such trials. The 
first clinical trial for SCI, started in 2009, run by Geron 
Corporation, USA, was approved by FDA despite contro-
versies regarding the ethical and safety concerns (forma-
tion of teratoma). The trial was based on the transplanta-
tion of human embryonic-derived oligodendrocyte 
progenitor cells (GRNOPC1) in four SCI patients be-
tween the ages of 18 and 65, with neurologically complete 
American Spinal Injury Association (ASIA) Impairment 
Scale grade A thoracic injuries. GRNOPC1 cells (dose of 
two million cells) were delivered by injection into the le-
sion site, between 7 and 14 days after injury. The patients 
were temporary immune-suppressed by low-dose tacroli-
mus. The results have shown the safety of the procedure, 
with no neurological recovery of the patients (Geron press 
release: ir.geron.com/phoenix.zhtml?c=67323&p=irol-
newsArticle&ID=1635760). 
Similar results have been obtained in clinical trials 
based on the transplantation of bone marrow derived 
mesenchymal stem cells, which have shown promising 
results in preclinical studies on different animals (rats, 
pigs, non-human primates) with improved locomotor 
performance. Nonetheless, the procedure has failed to 
show functional benefit to SCI patients in several studies 
(48).
The beneficial effects of autologous bulbar olfactory 
ensheating glial cells transplanted 21 months after injury 
to a 38-year-old male patient with complete traumatic 
SCI at upper vertebral level (ASIA A scale), have been 
reported, with motor improvement to ASIA C, improved 
trunk stability and partial recovery of voluntary move-
ments of lower extremities (79).
The clinical use of the iPSCs to cure SCI is still re-
stricted due to limited preclinical data (59) and the safety 
problems regarding their potential formation of teratomas 
or other neoplasms (14, 37). However, iPSCs are the sub-
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ject of intensive studies that have already shown interest-
ing, long-distance axonal growth of human iPSCs (iso-
lated from a healthy 86-year-old male and differentiated 
into neural stem cells) grafted into adult immunodeficient 
rats after experimental SCI (41).
For other types of stem cell, like for example umbilical 
cord and adipose derived mesenchymal stem cells, more 
pre-clinical studies are required before safety is estab-
lished for controlled clinical trials, to avoid undesired 
results such as development of the tumors in treated pa-
tients (5). Thus, it is of the great importance to perform 
well-defined clinical trials and to educate patients to re-
duce their attraction to unproven therapies (22).
A valid alternative to transplantation of exogenous cells 
at the site of lesion after SCI, could be the activation of 
the endogenous stem cells normally present in the mam-
malian spinal cord (49), since this is a non-invasive meth-
od that does not require immune suppression. Indeed, in 
lower vertebrates, which can completely and spontane-
ously recover after SCI, endogenous spinal stem cells play 
a major role in the regeneration process (50)
The neural stem cell potential in the adult mammalian 
caudal nervous system resides mainly within the popula-
tion of ependymal cells lining the spinal central canal 
(30). This region contains a pool of stem and progenitor 
cells that are readily activated and recruited after experi-
mental spinal damage (28). Even though their sustained 
adult neurogenesis was not observed, the adult spinal neu-
ral stem cells are recruited and proliferate after SCI (90) 
to produce scar-forming astrocytes and myelinating oli-
godendrocytes (49). They can also be pharmacologically 
(with growth factors) and genetically manipulated to 
stimulate neurogenesis and oligodendrogenesis (53). Re-
cent reports have indicated an important role of spinal 
endogenous stem cells in restricting the tissue damage 
and neural loss after injury through the formation of 
glial scar and exerting the neurotrophic effect required for 
survival of neurons adjacent to the lesion (61).
Although spinal cord endogenous NSPCs cells repre-
sent a potential source for future SCI treatments, there is 
the immediate need to fully identify them prior to any 
manipulation for their clinical recruitment. Useful data 
may come from an in vitro SCI models, in which novel 
molecules, such as transcription factors, were recently 
discovered to be involved in activation and migration of 
endogenous spinal stem cells after injury (51).
neurAl stem Cells for stroke 
therApy
Current preclinical evidence and clinical experience 
using various donor cell types show great promise for cell 
transplantation as a new therapeutic modality for stroke 
(29, 39). Multiple stem/progenitor cells have been tested 
in preclinical studies on animals as potential sources for 
cell based therapy for stroke and have demonstrated the 
ability to survive, mature, migrate to the lesion, and de-
crease neurological sequelae induced by stroke (39). The 
scientific community, conscious of the importance of de-
fining fundamental criteria related to the cell character-
ization, dosage, fate, safety, outcome measures, patient 
selection, therapeutic timing, etc., has prepared detailed 
guidelines for stroke clinical trials (STEPS Participants, 
2009), further revised more recently (64). The guidelines 
contain recommendations for both experimental and 
early-stage clinical studies on the cell therapy for stroke, 
with the goal to increase the reliability of the data (39).
Two recent reports have shown that transplantation of 
bone marrow mononuclear stem cells (56) and allogeneic 
mesenchymal stem cells from adipose tissue (17) into pa-
tients with acute ischemic stroke is safe, yet of no benefit 
to stroke outcome.
other AppliCAtions of nsCs to 
treAt Cns illnesses
Not only transplantation of neuronal stem cells, but 
other approaches like the so-called PharmaNutri-Neuro-
genesis (22) can be therapeutically pursued. Namely, since 
adult NSPCs are responsive to environmental stimuli, it 
has been proposed to protect or induce them with an ap-
propriate diet, behavior or with drugs (44, 60). Further-
more, various molecules and biomaterials with the poten-
tial to influence stem cell proliferation, differentiation and 
migration are explored as eventual supplements (22, 26, 
63).
ConClusions 
Former disappointing results from clinical studies ex-
ploring neuroprotective and neurorepair strategies to treat 
neurodegenerative diseases and brain and spinal cord in-
juries, should stimulate novel approaches aimed at ex-
ploiting the transplantation of exogenous neuronal stem 
cells, as well as the endogenous rewiring potential of the 
brain and spinal cord stem/progenitor cells. Even though 
ongoing clinical trials already indicate the feasibility of 
such therapeutic strategies, much more basic knowledge 
about the maintenance, quiescence, mobilization, migra-
tion, proliferation, differentiation and guidance of the 
neuronal stem cells is necessary to fully control future 
stem cell-based clinical interventions.
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